- Home
- HYI vs BDTX Comparison
HYI vs BDTX Comparison
Compare HYI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYI | BDTX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.8M | 116.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HYI | BDTX |
|---|---|---|
| Price | $10.74 | $2.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 45.2K | ★ 592.3K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 9.59% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.83 | $1.20 |
| 52 Week High | $12.12 | $4.94 |
Technical Indicators
Market Signals| Indicator | HYI | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.00 | 39.51 |
| Support Level | N/A | $1.93 |
| Resistance Level | $11.21 | $2.86 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 4.55 | 24.11 |
Price Performance
Historical ComparisonAbout HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.